Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: Contributions of polydrug use

Drug and Alcohol Dependence

Volumn 87, Issue 2-3, 2007, Pages 303-311

  Medina, Krista Lisdahl ^a,b   Shear, Paula K ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

3,4 Methylenedioxymethamphetamine; Adverse effects; Anxiety; Apathy; Depression; Disinhibition; Drug effects; Frontal behavioral syndromes; Gender differences; MDMA; Polydrug use

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS;

ADULT; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; BEHAVIOR; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EXPOSURE; ETHNICITY; FEMALE; HUMAN; MALE; MENTAL DISEASE; MULTIPLE DRUG ABUSE; PRIORITY JOURNAL; RATING SCALE; SELF REPORT; SEX DIFFERENCE; STATE TRAIT ANXIETY INVENTORY; SYMPTOM;

AFFECT; ANXIETY; BEHAVIORAL SYMPTOMS; DEPRESSION; FEMALE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PATIENT SELECTION; PERSONALITY INVENTORY; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

CANNABIS SATIVA;

EID: 33846822046     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2006.09.003     Document Type: Article

References (70)

1. Ahmadi J., Farrashbandi H., Menzies P., Majdi B., Ahmadi F., Babaee M.A., Esmaeelian G., Ahmadi M., Rahnama A., Ahmadi F., et al. Prevalence of mood and anxiety disorders in a sample of Iranian outpatient opioid addicts. German J. Psychiatry 8 1 (2005) 5-7
2. Beck A.T. Beck Depression Inventory. 2nd ed. (1996), Psychological Corporation, New York
3. Boyd C.J., McCabe S.E., and d'Arcy H. Ecstasy use among college undergraduates: gender, race, and sexual identity. J. Subst. Abuse Treat 24 (2003) 209-215
4. Brown G.L., Goodwin F.K., Ballenger J.C., Goyer P.F., and Major L.F. Aggression in humans correlates with cerebrospinal fluid metabolites. Psychiatry Res. 1 (1979) 131-139
5. Buchart R., Thomasius R., Wilke F., Petersen K., Nebeling B., Obrocki J., et al. A voxel-based PET investigation of the long-term effects of "ecstasy" consumption on brain serotonin transporters. Am. J. Psychiatry 161 7 (2004) 1181-1189
6. Callaly T., Trauer T., Munro L., and Whelan G. Prevalence of psychiatric disorder in a methadone maintenance population. Aust. N. Z. J. Psychiatry 35 (2001) 601-605
7. Coccaro E.F. Central serotonin and impulsive aggression. Br. J. Psychiatry 155 (1989) 52-62
8. Croft R.J., Klugman A., Baldeweg T., and Gruzelier J.H. Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users. Am. J. Psychiatry 158 10 (2001) 1687-1692
9. Croft R.J., Mackay A.J., Mills A.T.D., and Gruzelier J.G.H. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 153 (2001) 373-379
10. Curran H.V., and Travill R.A. Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction 92 7 (1997) 821-831
11. Curran V.H., Rees H., Hoare T., Hoshi R., and Bond A. Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology 173 (2004) 425-433
12. Daumann J., Pelz S., Becker S., Tuchtenhagen F., and Gouzoulis-Mayfrank E. Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. Hum. Psychopharmacol. 16 (2001) 627-633
13. Daumann J., Hensen G., Thimm B., Rezk M., Till B., and Gouzoulis-Mayfrank E. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology 173 (2004) 398-404
14. de Win M.M.L., Reneman L., Reitsma J.B., den Heeten G.J., Booij J., and van den Brink W. Mood disorders and serotonin transporter density in ecstasy users- the influence of long-term abstention, dose, and gender. Psychopharmacology 173 (2004) 376-382
15. Fals-Stewart W., O'Farrell T.J., Freitas T.T., McFarlin S.K., and Rutligliano P. The Timeline Followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J. Consult. Clin. Psychol. 68 1 (2000) 134-144
16. Fingeret M.C., Moeller F.G., and Stotts A. Gender differences among MDMA users on psychological and drug history variables. Addict Dis. Their Treat 4 2 (2005) 43-48
17. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J., 2001. Structured Clinical Interview for Axis I DSM-IV-TR Disorders, Patient ed. (With Psychotic Screen) SCID-I/P, New York, New York http://www.scid4.org/.
18. Fox H.C., McLean A., Turner J.D.D., Parrott A.C., Rogers R., and Sahakian B.J. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology 162 (2002) 203-214
19. Fukui S., Kiyoshi W., and Masaomi I. Dependency on organic solvents and AAITS long-term prognosis. J. Ment. Health 38 (1992) 39-45
20. Garber J., Keiley M.K., and Martin N.C. Developmental trajectories of adolescents' depressive symptoms: predictors of change. J. Consul. Clin. Psychol. 70 1 (2002) 79-95
21. Gerra G., Zaimovic A., Giucastro G., Maestri D., Monica C., Sartori R., Caccavari R., and Delsignore R. Serotonergic function after 3,4-methylenedioxymethamphetamine ('Ecstasy') in humans. Int. Clin. Psychopharmacol. 13 (1998) 1-9
22. Goodwin R.D., and Hasin D.S. Sedative use and misuse in the United States. Addiction 97 5 (2002) 555-562
23. Gouzoulis-Mayfrank E., Thimm B., Rezk M., Hensen G., and Daumann J. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003) 819-827
24. Grace J., and Malloy P.F. Frontal Systems Behavior Scale (FrSBe) (1999), Psychological Assessment Resources Inc., Odessa, FL
25. Grant B.F. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J. Subst. Abuse 7 4 (1995) 481-497
26. Hatzidimitriou G., McCann U.D., and Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treatment with 3,4-methylenedioxymethamphetamine 7 years previously: factors influencing abnormal recovery. J. Neurosci. 19 12 (1999) 5096-5107
27. Joe G.W., Garriott J.C., and Simpson D.D. Physical symptoms and psychological distress among inhalant users. Special Issue: Inhalant use by Mexican American Youth: Findings from a Longitudinal Study. Hisp. J. Behav. Sci. 13 3 (1991) 297-314
28. Johnston L.D., O'Malley P.M., and Bachman J.G. Monitoring the Future: National Survey Results on Drug Use, 1975-2000, vol. II: College Students and Young Adults Ages 19-40 (2001), National Institute on Drug Abuse, Bethesda, Maryland
29. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., and Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 23 (2003) 3095-3105
30. Lieb R., Schuetz C.G., Pfister H., von Sydow K., and Wittchen H. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend. 68 (2002) 195-207
31. Malloy P., and Grace J. A review of rating scales for measuring behavior change due to frontal systems damage. Cogn. Behav. Neurol. 18 1 (2005) 18-27
32. McCann U.D., Ridenour A., Shaham Y., and Ricaurte G.A. Serotonin neurotoxicity after 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10 2 (1994) 129-138
33. McCann U.D., Szabo Z., Scheffel U., Matthews W.B., Dannals R.F., Ravert H.T., Musachio J.L., Mertl M.M., and Ricaurte G.A. Positron tomographic evidence of toxic effects of MDMA ('Ecstasy') on brain serotonin neurons in human beings. Lancet 352 (1998) 1433-1437
34. 11C]DASB. Neuropsychopharmacology 30 (2005) 1741-1750
35. McCardle K., Luebbers S., Carter J.D., Croft R.J., and Stough C. Chronic MDMA (ecstasy) use, cognition, and mood. Psychopharmacology 173 (2004) 434-439
36. Milani R.M., Parrott A.C., Turner J.J.D., and Fox H. Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict Behav. 29 (2004) 965-971
37. Medina, K.L., Kavanagh, G., Shear, P.K., Corcoran, K., 2006 (submitted for publication). "Ecstasy" (MDMA) use among college students: risk factors, perceived consequences, subjective effects, and gender differences.
38. Medina K.L., Shear P.K., and Corcoran K. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective. J. Int. Neuropsychol. Soc. 11 (2005) 753-765
39. Montgomery C., Fisk J.E., Newcombe R., Wareing M., and Murphy P.N. Syllogistic reasoning performance in MDMA (ecstasy) users. Exp. Clin. Psychopharmacol. 13 2 (2005) 137-145
40. Morgan M.J. Recreational use of 'ecstasy' (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19 (1998) 252-264
41. Morgan M.J., McFie L., Fleetwood L.H., and Robinson J.A. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?. Psychopharmacology 159 (2002) 294-303
42. Naughton M., Mulrooney J.B., and Leonard B.E. A review of the role of serotonin receptors in psychiatric disorders. Hum. Psychopharmacol. Clin. Exp. 15 (2000) 397-416
43. Newson R. Parameters behind "non-parametric" statistics: Kendall's Tau, Somers' D and median differences. Stat. J. 1 1 (2001) 1-20
44. O'Shea E., Granados R., Esteban B., Colado M.I., and Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve. Neuropharmacology 37 (1998) 919-926
45. Parrott A.C. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum. Psychopharmacol. 16 (2001) 557-577
46. Parrott A.C., Milani R.M., Parmar R., and Turner J.J.D. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159 (2001) 77-82
47. Parrott A.C., Sisk E., and Turner J.J.D. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend. 60 (2000) 105-110
48. 123I]B-CIT SPECT-preliminary report. Psychopharmacology 159 (2002) 140-335
49. Reneman L., Booij J., de Bruin K., Reitsma J.B., de Wolff F., Gunning W.B., et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358 9296 (2001) 1864-1869
50. Reneman L., Endert E., de Bruin K., Lavalaye J., Feenstra M.G., de Wolff F., and Booij J. The acute and chronic effects of MDMA ("Ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26 3 (2002) 387-396
51. Rienour T.A. Inhalants: not to be taken lightly anymore. Curr. Opin. Psychiatry 18 (2005) 243-247
52. Roiser J.P., Cook L.J., Cooper J.D., Rubinsztein D.C., and Sahakian B.J. Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am. J. Psychiatry 162 (2005) 609-612
53. Roiser J.P., and Sahakian B.J. Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology 173 (2004) 411-417
54. Sakai J.T., Hall S.K., Mikulich-Gilbertson S.K., and Crowley T.J. Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems. J. Am. Acad. Child Adolesc. Psychiatry 43 9 (2004) 1080-1088
55. Sala M., and Braida D. Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. Pharmacol. Biochem. Behav. 81 (2005) 407-416
56. Schifano F., Di Furia L., Forza G., Minicucu N., and Bricolo R. MDMA (ecstasy) consumption in the context of poly-drug abuse: A report of 150 patients. Drug Alcohol Depend. 52 (1998) 85-90
57. Scheffel U., Lever J.R., Stathis M., and Ricaurte G.A. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology 31 9 (1992) 881-893
58. Scheffel U., Szabo Z., Mathews W.B., Finley P.A., Dannals R.F., Ravert H.T., Szabo K., Yuan J., and Ricaurte G.A. In vivo detection of short and long-term MDMA neurotoxicity-A Positron Emission Tomography study in the living baboon brain. Synapse 29 (1998) 183-192
59. Selby M.J., and Azrin R.L. Neuropsychological functioning in drug abusers. Drug Alcohol Depend. 50 (1998) 39-45
60. Spielberger C.D., Gorsuch R.L., and Lushene. Manual for the State-Trait Anxiety Inventory (1970), Consulting Psychologists Press Inc., Palo Alto
61. Sobell L.C., Maisto S.A., Sobell M.B., and Cooper A.M. Reliability of alcohol abusers' self-reports of drinking behavior. Behav. Res. Therapy 17 2 (1979) 157-160
62. Taffe M.A., Weed M.R., Davis S., Huitron-Resendiz S., Schroeder R., Parsons L.H., Henriksen S.J., and Gold L.H. Functional consequences of repeated 3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neuropsychopharmacology 24 3 (2001) 230-239
63. Thomasius R., Petersen K.U., Zapletalova P., Wartberg L., Zeichner D., and Schmoldt A. Mental disorders in current and former heavy ecstasy (MDMA) users. Addiction 100 (2005) 1310-1319
64. Topp L., Hando J., Dillon P., Roche A., and Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend. 55 1-2 (1999) 105-115
65. Verdejo-García A.J., López-Torrecillas F., de Arcos F.A., and Pérez-Garcia M. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict Behav. 30 (2005) 89-101
66. Verdejo-García A.J., López-Torrecillas F., Gimenéx C.O., and Pérez-Garcia M. Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. Neuropsychol. Rev. 14 1 (2004) 1-41
67. Verheyden S.L., Hadfield J., Calin T., and Curran H.V. Sub-acute effects of MDMA (3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences. Psychopharmacology 161 (2002) 23-31
68. Verkes R.J., Hengeveld M.W., van der Mast R.C., Fekkes D., and van Kempen G.M.J. Mood correlates with blood serotonin, but not with glucose measures in patients with recurrent suicidal behavior. Psychiatry Res. 80 (1998) 239-248
69. von Geusau N.A., Stalenhoef P., Huizinga M., Snel J., and Ridderinkhof K.R. Impaired executive function in male MDMA ("ecstasy") users. Psychopharmacology 175 (2004) 331-341
70. Young J.M., McGregor I.S., and Mallet P.E. Co-administration of THC and MDMA ('Ecstasy') synergistically disrupts memory in rats. Neuropsychopharmacology 30 (2005) 1475-1482